Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC (ExpMACs) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02356653

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC (ExpMACs)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:

The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved protocols that utilize CliniMACs technology for T depletion.

Study Date: 
Sun, 12/01/2013 to Wed, 01/01/2020
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Device: Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs) Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched. Other Name: CliniMACs